Welcome to BioLegend’s one-of-a-kind advanced search. Search by any one of the single fields below or narrow down your searches by using multiple parameters. Looking for an anti-mouse NK cell antibody for IHC? Or looking for a FITC-conjugated antibody against a human marker for dendritic cells to use for flow cytometry? Only BioLegend’s advanced search can provide you with the best answers. If you have further questions, please contact our technical service team at 858-768-5801.
Use this document lookup tool to find Current Product Datasheets, Certificates of Analysis, or MSDS for any antibody products you have purchased from BioLegend.
Use the search box below to perform a site search of BioLegend.com powered by Google™.
The antibody was purified by affinity chromatography, and conjugated with PE/Cy7 under optimal conditions. The solution is free of unconjugated PE/Cy7 and unconjugated antibody.
Concentration:
0.2 mg/ml
Storage & Handling:
The antibody solution should be stored undiluted at 4°C and protected from prolonged exposure to light. Do not freeze.
Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For immunofluorescent staining, the suggested use of this reagent is ≤ 1.0 µg per 106 cells in 100 µl. It is recommended that the reagent be titrated for optimal performance for each application.
COA:
Application Notes:
Additional reported applications (for the relevant formats) include: immunoprecipitation1,2, Western blotting1,2, and immunohistochemistry of acetone-fixed frozen sections.
Cy3, Cy5, Cy5.5 and Cy7 are subject to proprietary rights of GE Healthcare Bio-Sciences Corp. and Carnegie Mellon University and made and sold under license from GE Healthcare Bio-Sciences Corp. Sale of this product is licensed for research use only.
Application References:
1. Jones AT, et al. 1994. J. Immunol. 153:3426. (IP, WB) 2. Carlow DA, et al. 1999. J. Immunol. 163:1441. (IP, WB) 3. Onami TM, et al. 2002. J. Immunol. 168:6022. 4. van der Most RG, et al. 2003. Intl. Immunol. 15:119. 5. Chu VT, et al. 2007. J. Immunol. 179:5947. 6. Lang A, et al. 2008. J. Immunol. 180:4848. PubMed 7. Gibbert K, et al. 2010. J. Immunol. 185:6179. PubMed
C57BL/6 mouse splenocytes stained with 1B11 PE/Cy7
CD43, also known as Ly-48, Leukosialin, Sialophorin, Leukocyte Sialoglycoprotein, and gp115, is a large single chain of type I transmembrane glycoprotein with abundant O-glycosylation and sialylation sites. Due to variable glycosylation and sialylation, two isoforms of CD43 have been identified. The 115 kD glycoform of CD43 is expressed on most hematopietic cells including T lymphocytes, NK cells, monocytes, granulocytes, platelets, and CD5+ B cells. It does not present on resting B cells and erythrocytes. While the 130 kD glycoform is thought to be activation-associated form primarily expressed on myeloid cells, pre-B cells, and activated T cells. It has been reported that CD43 binds to CD54 and Siglec-1. CD43 plays dual roles in cell adhesion and anti-adhesion, as well as costimulation of T cell activation and survival, and induction of apoptosis of T cells and hematopoietic progenitors. The 1B11 antibody reacts with the activation-associated glycoform of CD43. The epitope recognized by 1B11 is also shared with desialylated CD45RB. This antibody is useful for differentiation of effector CD8 T cells and memory T cells.
Single chain of type I transmembrane glycoprotein with abundant O-glycosylation and sialylation sites, 115 kD and 130 kD glycoforms with different glycosylation and sialylation
Distribution:
Most hematopoietic cells including peripheral T cells, NK cells, granulocytes, monocytes, thymocytes, platelets, plasma cells, CD5+ B-1 cells and activated B cells, and hemotopoietic progenitor cells.
Function:
Play a dual roles in cell-cell adhesion and anti-adhesion, costimulation of cell activation and survival, induce apoptosis of T cells and hematopoietic progenitors
Ligand Receptor:
CD54, Siglec-1
Antigen References:
1. van den Berg TK, et al. 2001. J. Immunol. 166:3637. 2. Moore T, et al. 1994. J. Immunol. 153:4978. 3. Onami TM, et al. 2002. J. Immunol. 168:6022. 4. Tong J, et al. 2004. J. Exp. Med. 199:1277. 5. Jones AT, et al. 1994. J. Immunol. 153:3426.
*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/terms). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.
This data display is provided for general comparisons between formats. Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors. If you need assistance with selecting the best format contact our expert technical support team.
